21 min
Dr. Elizabeth O'Day, CEO of Olaris Company - Biomarker of Response Technology C-Sessions
-
- Health & Fitness
Dr. Elizabeth O'Day is the CEO and Founder of Olaris, Inc., a precision medicine company that uses a pioneering metabolomics platform and proprietary machine learning algorithms to fundamentally improve how disease is diagnosed and treated. Olaris identifies “biomarkers of response” (BoR) to stratify patients into optimal treatment groups, increasing survival rates, decreasing adverse events, and reducing unnecessary healthcare costs.
Outside of Olaris, Dr. O’Day plays an incredibly active role in partnering with government leaders and global organizations in advancing the field of precision medicine around the world. After founding Olaris, Dr. O’Day was invited to attend the first United State of Women Summit convened by the White House in 2016, and was recognized as a “nominated Change Maker.” She was also invited to participate in Vice President Joe Biden's Cancer Moonshot Summit to discuss collaborative ways “to end cancer as we know it.” In 2016, Dr. O’Day began serving as the co-chair of the World Economic Forum’s Global Future Council on Biotechnology. In this role, she has focused on leading the council in identifying policy opportunities capable of accelerating new biotech, and also guiding the dialogue about the implications of biotech advancements globally.
Dr. O’Day serves on the Personalized Medicine Coalition (PMC) Board of Directors. In this role, Dr. O’Day collaborates with stakeholders across academia, industry, and government to increase access to personalized medicine.
---
Support this podcast: https://podcasters.spotify.com/pod/show/randall-broad/support
Dr. Elizabeth O'Day is the CEO and Founder of Olaris, Inc., a precision medicine company that uses a pioneering metabolomics platform and proprietary machine learning algorithms to fundamentally improve how disease is diagnosed and treated. Olaris identifies “biomarkers of response” (BoR) to stratify patients into optimal treatment groups, increasing survival rates, decreasing adverse events, and reducing unnecessary healthcare costs.
Outside of Olaris, Dr. O’Day plays an incredibly active role in partnering with government leaders and global organizations in advancing the field of precision medicine around the world. After founding Olaris, Dr. O’Day was invited to attend the first United State of Women Summit convened by the White House in 2016, and was recognized as a “nominated Change Maker.” She was also invited to participate in Vice President Joe Biden's Cancer Moonshot Summit to discuss collaborative ways “to end cancer as we know it.” In 2016, Dr. O’Day began serving as the co-chair of the World Economic Forum’s Global Future Council on Biotechnology. In this role, she has focused on leading the council in identifying policy opportunities capable of accelerating new biotech, and also guiding the dialogue about the implications of biotech advancements globally.
Dr. O’Day serves on the Personalized Medicine Coalition (PMC) Board of Directors. In this role, Dr. O’Day collaborates with stakeholders across academia, industry, and government to increase access to personalized medicine.
---
Support this podcast: https://podcasters.spotify.com/pod/show/randall-broad/support
21 min